KR20210045423A - 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도 - Google Patents

질환 치료를 위한 릴루졸 경구 붕해 정제의 용도 Download PDF

Info

Publication number
KR20210045423A
KR20210045423A KR1020217007246A KR20217007246A KR20210045423A KR 20210045423 A KR20210045423 A KR 20210045423A KR 1020217007246 A KR1020217007246 A KR 1020217007246A KR 20217007246 A KR20217007246 A KR 20217007246A KR 20210045423 A KR20210045423 A KR 20210045423A
Authority
KR
South Korea
Prior art keywords
riluzole
cancer
administration
disease
vas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217007246A
Other languages
English (en)
Korean (ko)
Inventor
블라디미르 코릭
Original Assignee
바이오하벤 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오하벤 테라퓨틱스 리미티드 filed Critical 바이오하벤 테라퓨틱스 리미티드
Publication of KR20210045423A publication Critical patent/KR20210045423A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217007246A 2018-08-16 2019-08-15 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도 Ceased KR20210045423A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862764864P 2018-08-16 2018-08-16
US62/764,864 2018-08-16
PCT/US2019/046709 WO2020037152A1 (en) 2018-08-16 2019-08-15 Use of riluzole oral disintigrating tablets for treating diseases

Publications (1)

Publication Number Publication Date
KR20210045423A true KR20210045423A (ko) 2021-04-26

Family

ID=69525906

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007246A Ceased KR20210045423A (ko) 2018-08-16 2019-08-15 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도

Country Status (15)

Country Link
US (1) US20210315865A1 (https=)
EP (1) EP3836922B1 (https=)
JP (2) JP2021534160A (https=)
KR (1) KR20210045423A (https=)
CN (1) CN112584831A (https=)
AU (1) AU2019322889A1 (https=)
BR (1) BR112021002692A2 (https=)
CA (1) CA3109769A1 (https=)
EA (1) EA202190544A1 (https=)
ES (1) ES2987802T3 (https=)
IL (1) IL280657A (https=)
MX (2) MX2021001563A (https=)
PH (1) PH12021550218A1 (https=)
SG (1) SG11202100880VA (https=)
WO (1) WO2020037152A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7805969B2 (ja) * 2020-06-24 2026-01-26 バイオヘイブン・セラピューティクス・リミテッド 強迫性障害を治療するための組成物及び方法
US20240016783A1 (en) * 2020-10-05 2024-01-18 Icahn School Of Medicine At Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022103639A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177153B (zh) * 2021-12-20 2023-04-07 平顶山市第二人民医院 一种利鲁唑口崩片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US9241902B2 (en) * 2003-12-17 2016-01-26 R.P. Scherer Technologies, Llc Chewable soft capsules containing ungelatinized starch
ES2564187T3 (es) * 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
US9434704B2 (en) * 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
CN107735077A (zh) * 2014-11-21 2018-02-23 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
WO2016081472A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
KR102462638B1 (ko) * 2014-11-26 2022-11-03 메디시노바, 인크. 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
AU2018215056A1 (en) * 2017-01-31 2019-08-08 Charles E. Inturrisi D-methadone and its derivatives for use in the treatment of disorders of the nervous system

Also Published As

Publication number Publication date
AU2019322889A1 (en) 2021-03-04
EP3836922A1 (en) 2021-06-23
JP2021534160A (ja) 2021-12-09
CA3109769A1 (en) 2020-02-20
WO2020037152A1 (en) 2020-02-20
EP3836922A4 (en) 2022-05-04
EP3836922C0 (en) 2024-08-07
US20210315865A1 (en) 2021-10-14
ES2987802T3 (es) 2024-11-18
BR112021002692A2 (pt) 2021-05-11
IL280657A (en) 2021-03-25
MX2021001563A (es) 2021-06-15
CN112584831A (zh) 2021-03-30
MX2024007642A (es) 2024-07-04
SG11202100880VA (en) 2021-02-25
EP3836922B1 (en) 2024-08-07
EA202190544A1 (ru) 2021-06-18
JP2024010017A (ja) 2024-01-23
PH12021550218A1 (en) 2021-12-06

Similar Documents

Publication Publication Date Title
EP3836922B1 (en) Use of riluzole oral disintigrating tablets for treating diseases
Kim et al. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas
US20260014123A1 (en) Use of riluzole oral disintegrating tablets for treating diseases
EP4039247B1 (en) Sublingual formulation of riluzole
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
Sateia et al. Efficacy and clinical safety of ramelteon: an evidence-based review
JP7594045B2 (ja) 薬学的組成物
EP4483956B1 (en) TRORILUZOLE INTENDED FOR USE IN THE TREATMENT OF SPINOCEREBELLOUS ATAXIA 3 (SCA3)
JP2013501805A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
IT201800004108A1 (it) Composizione a base naturale per l’uso nel trattamento dello stress cronico caratterizzato da disturbi dell’umore e/o ansia
EA046859B1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
Danyeli et al. Ketamine in Psychiatric Disorders
CN107243010A (zh) 血红素在改善睡眠障碍的药物及保健食品中的应用
La Monaca et al. A case of mutism subsequent to cocaine abuse
KR20240167886A (ko) 산후 우울증의 치료를 위한 5-메톡시-n,n-다이메틸트립타민
Monti et al. Role of zolpidem in the management of primary and comorbid insomnia
Agrawal et al. Litfulo: Is An Innovative Medication
Rittenberger et al. Dexmedetomidine reduces shivering during mild hypothermia in waking subjects
Tacchini et al. P. 1.159 A multi-dimensional approach to major depression
Al-Tamimi Pharmacokinetics of Paroxetine Tablets in healthy Arabic Subjects
HK1243318B (en) Sublingual formulation of riluzole
HK1243318A1 (en) Sublingual formulation of riluzole

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000